Last checked at 4 Mar 2016 07:00
e-Therapeutics plc
("e-Therapeutics" or the "Company")
Notification of Full Year Results Date
Oxford and Newcastle, UK - 4 March 2016 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its full year results for the year ended 31 January 2016 on Tuesday, 22 March 2016.
A group analyst briefing will be held at 11:30am on Tuesday, 22 March 2016 at Instinctif Partners' offices at65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email
e-therapeutics@instinctif.com to register.
-Ends-
For more information, please contact:
e-Therapeutics plc Malcolm Young, CEO Steve Medlicott, Finance Director
| Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne Sewell / Jayne Crook / Emma Barlow | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery and development company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.
The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology and addressing drug resistance in targeted cancer therapies. The platform is yielding multiple, highly potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery.
e-Therapeutics is also advancing its most promising programmes through clinical trials. There is a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103; and a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The Company also has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; and ETS2400 in Hedgehog pathway inhibition.
The Company is fully funded to advance its existing development programmes in cancer and depression and a further programme from its discovery platform. It is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk